AstraZeneca, vowing it won't cut corners, begins large-scale US study of coronavirus vaccine

AstraZeneca is the latest coronavirus vaccine developer to start a large-scale efficacy study in the U.S., announcing late Monday that it has begun a Phase 3 trial testing the shot it licensed from the University of Oxford.